Abstract: The present disclosure relates to the in vitro differentiation of memory B cells to plasmablasts or plasma cells and genetic modification of these cells to express a protein of interest, such as a specific antibody or other protein therapeutic.

Abstract: Materials and methods for treating a patient to express a therapeutic agent comprising administering a Kupffer cell-suppressing substance in combination with a vehicle for introducing, into the patient, an exogenous nucleic acid comprising a sequence for expression of the agent.

Abstract: Disclosed are chimeric antigen receptors (CAR) specific to ?v?6 integrin which is uniquely expressed in a wide variety of cancers. Also disclosed are vectors to express the CAR and methods to use the CAR to treat patients suffering from cancer. The instant disclosure provides a CAR comprising a binding domain specific to ?v?6 integrin. In various exemplary embodiments, the ?v?6 specific binding domain comprises a sequence as defined by SEQ ID NOs. 1-12. In some embodiments, the CAR comprises one or more intracellular domains comprising 4-1 BB domain, CD3? domain, and CD28 domain. In some embodiments, the ?v?6 binding domain is fused to an Fc region by a glycine-serine linker. In these and other embodiments, the Fc region is substantially similar to an IgG4 or an IgG1 Fc region.

Abstract: The present disclosure relates to the in vitro differentiation of memory B cells to plasmablasts or plasma cells and genetic modification of these cells to express a protein of interest, such as a specific antibody or other protein therapeutic.

Abstract: Disclosed are chimeric antigen receptors (CAR) specific to ?v?6 integrin which is uniquely expressed in a wide variety of cancers. Also disclosed are vectors to express the CAR and methods to use the CAR to treat patients suffering from cancer. The instant disclosure provides a CAR comprising a binding domain specific to ?v?6 integrin. In various exemplary embodiments, the ?v?6 specific binding domain comprises a sequence as defined by SEQ ID NOs. 1-12. In some embodiments, the CAR comprises one or more intracellular domains comprising 4-1 BB domain, CD3? domain, and CD28 domain. In some embodiments, the ?v?6 binding domain is fused to an Fc region by a glycine-serine linker. In these and other embodiments, the Fc region is substantially similar to an lgG4 or an lgG1 Fc region.

Abstract: The present disclosure provides compositions and methods for transducing B cells. In particular, the present disclosure provides for vectors and methods for transducing resting B cells and methods for differentiating same to express a transgene of interest.

Abstract: The present disclosure provides compositions and methods for transducing B cells. In particular, the present disclosure provides for vectors and methods for transducing resting B cells and methods for differentiating same to express a transgene of interest.